| DB ID | MyCo_1344 |
| Title | Triacetylfusarinine C: A urine biomarker for diagnosis of invasive aspergillosis |
| Year | 2018 |
| PMID | 30267801 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | The study adhered to the Declaration of Helsinki, 2013, Good Clinical Practice, and was approved by the local ethics committees, Medical University Graz, Austria (EC-number 23– 343 ex 10/11), and University Hospital Wuerzburg, Germany (#233/14). |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Urine |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | Triacetylfusarinine C |
| Biomarker Full Name | Triacetylfusarinine C |
| Biomarker Type | Diagnostic |
| Biomolecule | Siderophore |
| Geographical Location | Multi-Location |
| Cohort | The analyzed urine samples included four samples of a probable IA patient collected in 2015 at the Division of Hematology, University Hospital of Wuerzburg, Germany, 44 samples of midstream urine from 24 hematological malignancy patients collected between 2012 and 2015 at the Division of Hematology, Medical University of Graz, Austria, and 15 samples from healthy volunteers collected in 2015. |
| Cohort No. | 24 Patients and 15 control |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive aspergillosis (IA) is the most common airborne fungal infection mainly affecting individuals with a suppressed immune system including those with prolonged neutropenia, and hematopoietic stem cell transplantation (1). IA is caused by infection with different Aspergillus species, with A. fumigatus accounting for ~90% of all cases. IA has become one of the leading causes of death in immunocompromised patients, with 6-week mortality rates of around 30%. |
| Technique | Electrophoresis |
| Analysis Method | Capillary electrophoresis (CE)-electrospray ionization (ESI)-mass spectrometry (MS) |
| ELISA kits | ELISA Kit- Platelia Aspergillus(Platelia Aspergillus Ag ELISA; Bio-Rad Laboratories, Munich, Germany) |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | Capillary electrophoresis (CE)-electrospray ionization (ESI)-mass spectrometry (MS) |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
